New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:25 EDTAMGN, MMMAmgen appoints David Meline CFO
Amgen (AMGN) announced the appointment of David W. Meline as EVP and CFO, effective July 21. He will be responsible for Amgen's finance and investor relations operations, reporting to Robert A. Bradway, chairman and CEO. Meline will succeed Michael A. Kelly, who served as acting CFO since January 2014. Meline joins Amgen from 3M Company (MMM), where he most recently served SVP and CFO, responsible for all financial activities for 3M across 70 countries of operation.
News For AMGN;MMM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
11:36 EDTAMGNRumor: Amgen moves up on speculation of an investor stake
Subscribe for More Information
07:03 EDTAMGNCelgene leaps forward in immuno-oncology with Juno deal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said that Celgene (CELG) effectively spent $1B to buy into adoptive T cell therapy and own all of Juno Therapeutics' (JUNO) opportunities outside the U.S., leaping the company into a leading position in the immuno-oncology space. Schimmer additionally thinks Celgene's transaction should help boost investor confidence about the utility and value of CAR and TCR therapies, noting that he sees Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), bluebird bio (BLUE) and the Amgen (AMGN)-Kite Pharma (KITE) partnership as best positioned to compete in this rapidly advancing field. The analyst keeps an Overweight rating and $144 price target on Celgene.
June 25, 2015
17:00 EDTMMM3M files patent infringement lawsuit in Germany for dental ceramic technology
3M has filed a patent infringement lawsuit in Düsseldorf, Germany, against Zirkonzahn Deutschland GmbH located in Neuler, Germany, and Zirkonzahn SRL located in Gais, South Tyrol, Italy. The lawsuit alleges infringement of 3M’s European Patent No. 1 154 969 B2 by using Zirkonzahn’s instructions for sintering of Zirkonzahn’s zirconia blocks. 3M’s patented technology enables dimensionally precise sintering of dental ceramics.
June 24, 2015
07:56 EDTAMGNAmgen management to meet with Evercore ISI
Subscribe for More Information
June 23, 2015
09:03 EDTMMM3M to buy Capital Safety from KKR in deal valued at $2.5B
3M (MMM) announced it has entered into a definitive agreement to acquire Capital Safety from KKR (KKR) for a total enterprise value of $2.5B, including the assumption of approximately $700M of debt, net of cash acquired. The business employs approximately 1,500 people worldwide and is headquartered in Bloomington, Minnesota. On a GAAP reported basis, 3M estimates the acquisition to be 4c dilutive to earnings in the first 12 months following completion of the transaction. Excluding purchase accounting adjustments and anticipated one-time expenses related to the transaction and integration, 3M estimates the acquisition to be 12c accretive to earnings over the same period. The transaction is expected to close in the third quarter, subject to customary closing conditions and regulatory approvals. 3M will finance the transaction with existing cash, a portion of which will come from outside the U.S.
07:25 EDTAMGNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
14:31 EDTMMM3M files patent infringement suit in Korea against LMS Co. Ltd.
3M Innovative Properties Co. and 3M Korea Ltd. filed a patent infringement lawsuit on June 19 in the Seoul Central District Court against LMS Co. Ltd. The suit alleges that certain LMS Co. Ltd. light management film package products, including a light management film package product sold under the product name of “XLAS,” infringe 3M’s Korean Patent No. 1,074,570 titled "Method for Stacking Surface Structured Optical Films." 3M’s microreplicated stacked prism films, including 3M Advanced Structured Optical Composites (ASOC), are integrated into LCD displays. The prism films direct light to enable a thinner and more energy-efficient electronic display.
June 19, 2015
16:02 EDTAMGNAmgen presents open-label extension data for Phase 2 study of migraine treatment
Subscribe for More Information
07:23 EDTAMGNTeva data quite strong, says Bernstein
After Teva (TEVA) announced data for its TEV-48125 drug in episodic migraine, Bernstein notes that the drug met its primary and secondary endpoints. The firm says that the reduction in migraine days of Teva's drug appears to be higher than what Amgen (AMGN) and Lilly (LLY) have shown. The firm continues to see the migraine treatments from Teva and Alder as better than those from Lilly and Amgen.
June 18, 2015
16:06 EDTAMGNAmgen says Phase 3 trial of Vectibix met primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use